Seres’ SER-155 receives breakthrough status for BSIs reduction
The designation was based on the Phase Ib clinical trial’s positive outcomes. Credit: Pickadook/Shutterstock. Seres Therapeutics has received US Food and Drug Administration (FDA) breakthrough